The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Neoadjuvant pembrolizumab for cisplatin-ineligible muscle-invasive bladder cancer prior to radical cystectomy.
 
Kyle M Rose
Employment - Urogen pharma
 
Marco Bandini
No Relationships to Disclose
 
Heather L Huelster
No Relationships to Disclose
 
Giuseppe Basile
No Relationships to Disclose
 
Shreyas U Naidu
No Relationships to Disclose
 
Philippe E. Spiess
Leadership - Global Society of Rare Genitourinary Tumors; NCCN
Honoraria - UptoDate
Other Relationship - NCCN
(OPTIONAL) Uncompensated Relationships - Moffitt Cancer Center
 
Andrea Necchi
Employment - Bayer (I)
Stock and Other Ownership Interests - Bayer (I)
Honoraria - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Foundation Medicine; Janssen; Merck; Roche
Consulting or Advisory Role - AstraZeneca; Basilea Pharmaceutical; Bayer; Bristol-Myers Squibb; Catalym; Clovis Oncology; GlaxoSmithKline; Incyte; Janssen; Merck Sharp & Dohme; Rainier Therapeutics; Roche; Seattle Genetics/Astellas
Research Funding - AstraZeneca (Inst); Gilead Sciences; Ipsen; Merck Sharp & Dohme (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Janssen; Merck Sharp & Dohme; Pfizer; Rainier Therapeutics; Roche
Other Relationship - Bayer (I)
 
Roger Li
Stock and Other Ownership Interests - crispr therapeutics; Guardant Health
Consulting or Advisory Role - Arquer Diagnostics; Bristol-Myers Squibb; FerGene; Ferring
Research Funding - CG Oncology
Expert Testimony - CG Oncology
Other Relationship - Predicine